Evidence map›Paper›PMID 35217172›Full record

ArticleMolecular & cellular proteomics : MCP2022

Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression.

James R Byrnes, Amy M Weeks, Eric Shifrut, Julia Carnevale, Lisa Kirkemo, Alan Ashworth, Alexander Marson, James A Wells

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Tumor-driven stabilization of CD8Frontiers in immunology · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. CD8Journal of translational medicine · 2024
    Review
  17. Challenges and new technologies in adoptive cell therapy.Journal of hematology & oncology · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

James R ByrnesDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
Amy M WeeksDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
Eric ShifrutDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA; Gladstone Institutes, San Francisco, California, USA.
Julia CarnevaleDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Lisa KirkemoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA.
Alan AshworthDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA; The Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
Alexander MarsonDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California, USA; Gladstone Institutes, San Francisco, California, USA; Department of Medicine, University of California, San Francisco, San Francisco, California, USA; The Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, California, USA; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA; Chan Zuckerberg Biohub, San Francisco, California, USA.
James A WellsDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California, USA; Chan Zuckerberg Biohub, San Francisco, California, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California, USA. Electronic address: jim.wells@ucsf.edu.
University of California, San Francisco · USGladstone Institutes · US

Funding

Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
Characterizing and Targeting the Hypoxic T Cell Surfaceome to Promote Immune Function in CancerF32CA239417 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BYRNES, JAMES ROBERT · 2019 to 2021
$191k
NCI NIH HHS F32 CA239417NIGMS NIH HHS R35 GM122451
6 · The paper itself

Abstract

Immunosuppressive factors in the tumor microenvironment (TME) impair T cell function and limit the antitumor immune response. T cell surface receptors and surface proteins that influence interactions and function in the TME are proven targets for cancer immunotherapy. However, how the entire surface proteome remodels in primary human T cells in response to specific suppressive factors in the TME remains to be broadly and systematically characterized. Here, using a reductionist cell culture approach with primary human T cells and stable isotopic labeling with amino acids in cell culture-based quantitative cell surface capture glycoproteomics, we examined how two immunosuppressive TME factors, regulatory T cells (Tregs) and hypoxia, globally affect the activated CD8

Indexed as

ProteomeT-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesHumansHypoxiaTumor MicroenvironmentProteomecell surface proteomicshypoxiaT cellstumor microenvironment

Identifiers

PMID35217172
PMCPMC9006863
OpenAlexW4214596652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.